XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93

Shares of XOMA Co. (NASDAQ:XOMA) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $19.93 and traded as high as $24.62. XOMA shares last traded at $24.38, with a volume of 7,113 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $74.00 price objective on shares of XOMA in a research report on Friday, February 16th.

XOMA Price Performance

The business has a 50-day moving average of $24.19 and a two-hundred day moving average of $19.93. The firm has a market cap of $283.78 million, a P/E ratio of -6.03 and a beta of 0.58. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The company had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.01 million. On average, sell-side analysts anticipate that XOMA Co. will post -1.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA

A number of institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of XOMA by 40.7% in the 4th quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 689 shares during the period. UBS Group AG lifted its stake in shares of XOMA by 23.5% in the 1st quarter. UBS Group AG now owns 3,632 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 691 shares during the period. BNP Paribas Arbitrage SA lifted its stake in shares of XOMA by 81.8% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,449 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,102 shares during the period. Northern Trust Corp lifted its stake in shares of XOMA by 1.3% in the 3rd quarter. Northern Trust Corp now owns 87,208 shares of the biotechnology company’s stock valued at $1,229,000 after purchasing an additional 1,133 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of XOMA by 118.3% in the 4th quarter. BNP Paribas Financial Markets now owns 2,277 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 1,234 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.